SCHEMBL17832297

SCHEMBL17832297

Cc1[nH]c(-c2ccc(N)nc2F)nc1F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC9A1 P19634 3/20 0.36
▸ NOS3 P29474 2/20 0.34
▸ NOS2 P35228 2/20 0.34
▸ NOS1 P29475 1/20 0.34
▸ F11 P03951 2/20 0.33
▸ PIM1 P11309 3/20 0.33
▸ PIM2 Q9P1W9 2/20 0.33
▸ PIM3 Q86V86 1/20 0.33
▸ MGAM O43451 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ SI P14410 1/20 0.33
▸ MGAM2 Q2M2H8 1/20 0.33
▸ AMY1A P0DUB6 2/20 0.32
▸ ADORA2A P29274 1/20 0.32
▸ ADORA1 P30542 1/20 0.32
▸ NPC1 O15118 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ PKM P14618 1/20 0.30
▸ RAB9A P51151 1/20 0.30
▸ L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24427630 0.90 SLC9A1 (0.35) SLC9A1NOS3NOS2NOS1F11
SCHEMBL24427896 0.73 PIK3CD (0.43) NOS3NOS2NPC1PKMRAB9A
SCHEMBL17832296 0.72 NOS3 (0.34) NOS3NOS2NOS1PIM1PIM2
SCHEMBL24427493 0.72 NOS3 (0.32) NOS3NOS2NOS1PIM1PIM2
SCHEMBL24427894 0.71 RPS6KA3 (0.49) GAAADORA1NPC1ALDH1A1PKM
SCHEMBL24427823 0.70 PIM2 (0.39) NOS3NOS2NOS1F11PIM1
SCHEMBL91461 0.66 — —
SCHEMBL24726301 0.66 PIM1 (0.31) PIM1PIM2PIM3
SCHEMBL27320819 0.64 NOS3 (0.41) NOS3NOS2NOS1PIM1PIM2
SCHEMBL24103788 0.63 BRD4 (0.42) NOS3NOS2NOS1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230138003-A1 DIHYDROINDOLIZINONE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2023-05-04 — — US disclosed
US-11566027-B2 Dihydroindolizinone derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2023-01-31 — — US disclosed
US-11518766-B2 Tricyclic compound, preparation method therefor and use thereof SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD. (CN) 2022-12-06 — — US disclosed
EP-3998263-A1 TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) 2022-05-18 — — EP disclosed
US-20210009586-A1 DIHYDROINDOLIZINONE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2021-01-14 — — US disclosed
US-10815233-B2 Dihydroindolizinone derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2020-10-27 — — US disclosed
EP-3702357-A1 DIHYDROINDOLIZINONE DERIVATIVE ONO Pharmaceutical Co., Ltd. (JP) 2020-09-02 — — EP disclosed
US-20200140435-A1 DIHYDROINDOLIZINONE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2020-05-07 — — US disclosed
US-10550119-B2 Dihydroindolizinone derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2020-02-04 — — US disclosed
US-20190352304-A1 DIHYDROINDOLIZINONE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2019-11-21 — — US disclosed
US-10407426-B2 Dihydroindolizinone derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2019-09-10 — — US disclosed
US-20170349580-A1 DIHYDROINDOLIZINONE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2017-12-07 — — US disclosed
EP-3231803-A1 DIHYDROINDOLIZINONE DERIVATIVE ONO Pharmaceutical Co., Ltd. (JP) 2017-10-18 — — EP disclosed
WO-2016093285-A1 DIHYDROINDOLIZINONE DERIVATIVE 小野薬品工業株式会社 2016-06-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170349580-A1 DIHYDROINDOLIZINONE DERIVATIVE CYP2C19, CYP4A22, CYP4A11 SLC9A1 427/4885NOS3 151/4885NOS2 121/4885
US-10815233-B2 Dihydroindolizinone derivative CYP2C19, CYP4A22, CYP4A11 SLC9A1 427/4885NOS3 151/4885NOS2 121/4885
US-20190352304-A1 DIHYDROINDOLIZINONE DERIVATIVE CYP2C19, CYP4A22, CYP4A11 SLC9A1 427/4885NOS3 151/4885NOS2 121/4885
US-20200140435-A1 DIHYDROINDOLIZINONE DERIVATIVE CYP2C19, CYP4A22, CYP4A11 SLC9A1 427/4885NOS3 151/4885NOS2 121/4885
US-10407426-B2 Dihydroindolizinone derivative CYP2C19, CYP4A22, CYP4A11 SLC9A1 427/4885NOS3 151/4885NOS2 121/4885
US-20230138003-A1 DIHYDROINDOLIZINONE DERIVATIVE TFPI, F2, TFPI2 SLC9A1 335/4885NOS3 130/4885NOS2 82/4885
US-20210009586-A1 DIHYDROINDOLIZINONE DERIVATIVE CYP2C19, CYP4A22, CYP4A11 SLC9A1 427/4885NOS3 151/4885NOS2 121/4885
US-11518766-B2 Tricyclic compound, preparation method therefor and use thereof TFPI, TFPI2, F11 SLC9A1 562/4885NOS3 3789/4885NOS2 2771/4885
US-11566027-B2 Dihydroindolizinone derivative CYP2C19, CYP4A22, CYP4A11 SLC9A1 427/4885NOS3 151/4885NOS2 121/4885
US-10550119-B2 Dihydroindolizinone derivative CYP2C19, CYP4A22, CYP4A11 SLC9A1 427/4885NOS3 151/4885NOS2 121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback